J. Hilton

Second-look laparotomy in ovarian cancer: evaluation of pathologic variables.

G. Malkasian, K. Podratz, J. Hilton, 1985, American journal of obstetrics and gynecology.

Randomized phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma.

J. Edmonson, G. Malkasian, J. A. Jefferies, 1987, Gynecologic oncology.

Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo.

D. Tu, W. Parulekar, M. Moore, 2012, European journal of cancer.

Randomized Phase II studies of cisplatin and a combination of cyclophosphamide‐doxorubicin‐cisplatin (CAP) in patients with progestin‐refractory advanced endometrial carcinoma

J. Edmonson, J. Krook, J. Hilton, 1988 .

An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib.

L. Seymour, F. Shepherd, D. Tu, 2013, Lung cancer.

An evaluation of the possible interaction of gastric acid suppressive medication and the EGFR tyrosine kinase inhibitor erlotinib.

L. Seymour, F. Shepherd, D. Tu, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.